Allstate Corp Grows Stock Holdings in Johnson & Johnson $JNJ

Allstate Corp increased its stake in Johnson & Johnson (NYSE:JNJ) by 1,554.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 86,872 shares of the company’s stock after purchasing an additional 81,622 shares during the quarter. Allstate Corp’s holdings in Johnson & Johnson were worth $16,108,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Violich Capital Management Inc. increased its position in Johnson & Johnson by 8.4% during the third quarter. Violich Capital Management Inc. now owns 95,736 shares of the company’s stock valued at $17,751,000 after acquiring an additional 7,400 shares during the last quarter. NorthCrest Asset Manangement LLC grew its stake in shares of Johnson & Johnson by 2.1% during the 3rd quarter. NorthCrest Asset Manangement LLC now owns 250,912 shares of the company’s stock valued at $47,395,000 after purchasing an additional 5,185 shares during the period. Wealth Enhancement Advisory Services LLC increased its position in shares of Johnson & Johnson by 7.0% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 1,844,421 shares of the company’s stock valued at $348,393,000 after purchasing an additional 120,335 shares during the last quarter. DeDora Capital Inc. lifted its stake in shares of Johnson & Johnson by 3.3% in the 3rd quarter. DeDora Capital Inc. now owns 6,095 shares of the company’s stock worth $1,130,000 after purchasing an additional 197 shares during the period. Finally, JCIC Asset Management Inc. purchased a new position in shares of Johnson & Johnson in the third quarter worth approximately $58,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on JNJ. Citigroup upped their target price on shares of Johnson & Johnson from $215.00 to $232.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Royal Bank Of Canada set a $240.00 price objective on Johnson & Johnson in a research note on Wednesday, December 17th. Sanford C. Bernstein lifted their target price on Johnson & Johnson from $193.00 to $208.00 and gave the company a “market perform” rating in a research report on Friday, January 9th. The Goldman Sachs Group boosted their price target on Johnson & Johnson from $213.00 to $240.00 and gave the company a “buy” rating in a report on Thursday, December 18th. Finally, Johnson Rice set a $190.00 price objective on Johnson & Johnson and gave the stock a “hold” rating in a research note on Wednesday, October 22nd. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $213.33.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Q4 revenue beat and 2026 guidance above consensus — management raised FY2026 sales and EPS targets, signaling mid‑single‑digit organic growth and margin improvement. Johnson & Johnson reports Q4 and Full-Year 2025 results
• Positive Sentiment: MedTech and oncology drove top‑line strength (MedTech up mid‑single digits; strong Darzalex and other cancer drug growth), supporting the company’s revenue trajectory beyond STELARA. Johnson & Johnson Says Product Launches, Regulatory Approvals Drive Growth
• Positive Sentiment: Technicals and analyst sentiment remain constructive — MarketBeat highlights a trend‑following buy signal and rising analyst price targets, which could limit downside and support future upside. Johnson & Johnson Quietly Triggers a Trend Following Buy Signal
• Neutral Sentiment: EPS outcome was mixed: adjusted EPS roughly in line (small beat vs. some consensus figures) and margins broadly as expected — solid but not overpowering enough to eliminate near‑term concerns. Johnson & Johnson (JNJ) Tops Q4 Earnings and Revenue Estimates
• Negative Sentiment: Talc litigation advanced this week as plaintiffs cleared a key expert testimony hurdle — a reminder of legacy legal risk that can create episodic share pressure and potential liabilities. Johnson & Johnson Talc Plaintiffs Clear Key Expert Testimony Hurdle
• Negative Sentiment: STELARA sales plunged after loss of exclusivity and biosimilar competition (material YOY decline), which is a sizable headwind given STELARA’s previous revenue contribution. That dynamic is a key reason shares traded down despite the beat. J&J Stock Down Despite Q4 Earnings Beat, Oncology Drugs Drive Sales
• Negative Sentiment: Company flagged a hit from a recent drug‑pricing deal with the administration (described as “hundreds of millions” of dollars), which tempers net profit upside and adds near‑term uncertainty. Johnson & Johnson forecasts 2026 profit above Wall Street estimates

Johnson & Johnson Stock Down 0.0%

Shares of JNJ stock opened at $218.12 on Thursday. The company’s fifty day simple moving average is $207.39 and its two-hundred day simple moving average is $188.27. Johnson & Johnson has a 52 week low of $141.50 and a 52 week high of $220.11. The stock has a market cap of $525.52 billion, a P/E ratio of 21.05, a PEG ratio of 2.24 and a beta of 0.34. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.46. The firm had revenue of $24.56 billion for the quarter, compared to analysts’ expectations of $24.14 billion. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business’s revenue was up 9.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.04 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. Analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.